相关实验视频
Updated: May 26, 2025

06:35
Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 24, 2010
16.8K
在认知无损的样本中SCD-plus特征和AD生物标志物:对9个队列研究的元分析方法
Elizabeth Kuhn1,2, Hannah M Klinger3, Rebecca E Amariglio3,4
1German Center for Neurodegenerative Diseases (DZNE) Bonn, Bonn, Germany.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 22, 2025
概括
主观认知衰退加 (SCD-plus) 特性可以信号临床前阿尔茨海默病 (AD). 多个SCD-plus特征强烈表明在认知不受损的老年人中异常的AD生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 生物标志物 生物标志物
背景情况:
- 主观认知衰退加 (SCD-plus) 特性是临床前阿尔茨海默病 (AD) 的潜在指标.
- 有限的研究存在于SCD-plus特征和AD生物标志物在认知不受损 (CU) 的老年人之间的关联.
研究的目的:
- 研究CU老年人中SCD-plus特征和AD生物标志物 (粉样β和tau) 之间的关系.
- 为了确定特定的SCD-plus特征是否与临床前AD相关.
主要方法:
- 来自9个队列 (n=7219) 的横截面数据的元分析.
- 检查了SCD-plus特征与正子发射断层扫描 (PET) 或脑脊液 (CSF) 衍生的粉样蛋白β (Aβ) 和生物标志物之间的关联.
主要成果:
- 患有临床前AD的参与者更有可能报告SCD-plus特征.
- 自我报告的记忆力下降和焦虑与较高的Aβ水平有关.
- 更多的SCD-plus特征与高的Aβ和异常的tau水平相关.
结论:
- 多个SCD-plus特征是CU老年人异常AD生物标志物的强有力的指标.
- 孤立的SCD特征可能主要反映了Aβ升高,这表明它们作为临床前AD的早期行为标志物的实用性.
- SCD-plus特征在识别阿尔茨海默病早期生物阶段方面表现有前途.
相关概念视频
Alzheimer's Disease: Overview
425
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
425
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95

